Fertility Sparing Management of EndomeTrial Cancer and Hyperplasia

What this study is about

This study protocol evaluates the use of hysteroscopic endomyometrial resection in women diagnosed with atypical endometrial hyperplasia or grade I endometrial cancer who have not responded to anti-hormone therapy. Patients in this study wish to preserve fertility.

Who can join (things the study team will check)

✅ You may be able to join if…

• Age less than 40 years
• Pathologist confirmed biopsy evidence of one of the following:
  • Grade I endometrial endometrioid adrenocarcinoma (EC) with less than 1/3 of the endometrial surface involved.
  • Atypical endometrial hyperplasia (AH)
• MRI demonstrating less than 1/3 myometrial invasion if the patient has EC
• Absence of significant surgical co-morbidities e.g. pulmonary hypertension, significant cardiac valvular disease, or contraindication to surgery.
• Desire to preserve fertility
• Reasonable chance to conceive based on consultation with an infertility specialist
• Adequate dose and duration of progesterone therapy prior to enrolment:
• Adequate dose:
  • Medroxyprogesterone acetate (Provera; 200mg/day)
  • Megestrol acetate (Megace; 160mg/day)
• Adequate duration: 6 months
• Failure of progestin therapy defined as:
  • Unsuccessful eradication of hyperplasia or cancer in the uterus
  • Intolerance to the side effects
• Signed informed consent

🚫 You may not be able to join if…

• Age 40 years and over
• Grade 2 or 3 endometrioid endometrial adenocarcinoma or non-endometrioid pathology
• Greater than 1/3 involvement of the endometrial surface in patients with Grade I EC
• Women who are not able to provide informed consent
• Women without pathologic confirmation of low-grade endometrioid carcinoma or AH
• Myometrial invasion on MRI greater than 1/3 total myometrial thickness.
• MRI evidence of ovarian or adnexal involvement
• The diagnosis of another cancer or medical condition that would interfere with the assessment of the hysteroscopic surgery success rates.
• Significant underlying fertility impairment that would significantly interfere with the success rate of HR

Where this trial is running

• Vancouver General Hospital, Vancouver, British Columbia, Canada

Who to contact

Neeraj Mehra, MD · 604-875-5508 · neeraj.mehra@ubc.ca

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT04362046.